Patents by Inventor Shu-Hui Liu
Shu-Hui Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240111709Abstract: A method for automatically setting addresses suitable for an RS485 system is provided. The RS485 system includes a host device and a plurality of slave devices. The method includes the following stages. The host device confirms that there are no addresses of the slave devices in a database. The slave devices are turned on in sequence. The slave devices calculate their own respective power-on times. The slave device enter an idle state during the period associated with the power-on time. Only one of the slave devices sends the power-on time to the host device when said slave device leaves the idle state. The host device sets the address of said slave device according to the power-on time when said slave device leaves the idle state.Type: ApplicationFiled: July 31, 2023Publication date: April 4, 2024Inventors: Shu-Hui LIU, Chia-Yang LIANG
-
Publication number: 20240093267Abstract: A high-throughput automated preprocessing method and a system are applied to a nucleic acid preprocessing apparatus including a control system, a sample transfer area, a nucleic acid extraction area, and a reagent setup area. The control system includes a user interface and guides a user to set up on the user interface. In the sample transfer area, the method includes steps of: a user selecting a sampling tube type, a test protocol and an extraction protocol on the user interface, and the control system performing a sample transfer task. In the nucleic acid extraction area, the method includes steps of: the control system performing a nucleic acid extraction task based on the selected extraction protocol. In the reagent setup area, the method includes steps of: the control system performing a reagent deployment task based on the selected test protocol, and the control system performing a nucleic acid transfer task.Type: ApplicationFiled: September 19, 2023Publication date: March 21, 2024Inventors: Wei-Te Hsieh, Chia-Yen Lin, Kuang-An Wang, Keng-Ting Liu, Shu-Hui Huang
-
Patent number: 11915977Abstract: A stacked integrated circuit (IC) device and a method are disclosed. The stacked IC device includes a first semiconductor element. The first substrate includes a dielectric block in the first substrate; and a plurality of first conductive features formed in first inter-metal dielectric layers over the first substrate. The stacked IC device also includes a second semiconductor element bonded on the first semiconductor element. The second semiconductor element includes a second substrate and a plurality of second conductive features formed in second inter-metal dielectric layers over the second substrate. The stacked IC device also includes a conductive deep-interconnection-plug coupled between the first conductive features and the second conductive features. The conductive deep-interconnection-plug is isolated by dielectric block, the first inter-metal-dielectric layers and the second inter-metal-dielectric layers.Type: GrantFiled: April 12, 2021Date of Patent: February 27, 2024Assignee: TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD.Inventors: Shu-Ting Tsai, Jeng-Shyan Lin, Dun-Nian Yaung, Jen-Cheng Liu, Feng-Chi Hung, Chih-Hui Huang, Sheng-Chau Chen, Shih Pei Chou, Chia-Chieh Lin
-
Publication number: 20240010743Abstract: Provided antibodies or antigen-binding fragment thereof specific for the variant exon v9 of the CD44 gene (CD44v9), antibody-drug-conjugate (ADC), and other derivative comprising the antibodies or antigen-binding fragment. Provided nucleic acid molecules encoding the same, and methods of making the same. Further provided pharmaceutical compositions comprising the same, and the use of the same in treating diseases or in the manufacture of a medicament for the treatment of the diseases, such as cancer.Type: ApplicationFiled: August 28, 2020Publication date: January 11, 2024Inventors: Xun Meng, Shu-Hui Liu
-
Publication number: 20220049008Abstract: Antibodies having binding specificity to CD44 v7/8, (a.k.a. CD44 variant 7/8) and antibody-drug conjugates (ADCs) or chimeric antigen receptors comprising such. Also provided herein are uses the anti-CD44 v7/8 antibodies, the ADCs, or immune cells expressing the chimeric antigen receptors for therapeutic and diagnostic purposes.Type: ApplicationFiled: July 27, 2021Publication date: February 17, 2022Applicant: Multitude Inc.Inventors: Shaofei Zhang, Bing Hou, Guangcun Cheng, Shu-Hui Liu, Xun Meng
-
Publication number: 20220041748Abstract: Antibodies specific to MUC18 (a.k.a. MCAM or CD146) and uses thereof for therapeutic and diagnostic purposes are provided. Also provided herein are chimeric antigen receptors (CARs) comprising an extracellular antigen-binding fragment that binds MUC18 and immune cells expressing such.Type: ApplicationFiled: June 17, 2021Publication date: February 10, 2022Applicant: Multitude Inc.Inventors: Bing Hou, Peng Chen, Junli Liu, Shu-Hui Liu, Xun Meng
-
Publication number: 20220041749Abstract: Antibodies specific to MUC18 (a.k.a. MCAM or CD146) and antibody-drug conjugates (ADCs) comprising such. Also provided herein are uses the the anti-MUC18 antibodies or ADCs for therapeutic and diagnostic purposes.Type: ApplicationFiled: June 17, 2021Publication date: February 10, 2022Applicant: Multitude Inc.Inventors: Bing Hou, Guangcun Cheng, Shaofei Zhang Zhang, Na Wang, Shu-Hui Liu, Xun Meng
-
Patent number: 11091544Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: GrantFiled: September 7, 2018Date of Patent: August 17, 2021Assignee: Rinat Neuroscience Corp.Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
-
Publication number: 20210115159Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.Type: ApplicationFiled: November 18, 2020Publication date: April 22, 2021Applicants: PFIZER INC., RINAT NEUROSCIENCE CORP.Inventors: Pavel STROP, Magdalena Grazyna DORYWALSKA, Arvind RAJPAL, David SHELTON, Shu-Hui LIU, Jaume PONS, Russell DUSHIN
-
Patent number: 10941216Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.Type: GrantFiled: May 11, 2017Date of Patent: March 9, 2021Assignee: Pfizer Inc.Inventors: Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Shelton, Shu-Hui Liu, Jaume Pons, Russell Dushin
-
Patent number: 10927178Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.Type: GrantFiled: August 8, 2019Date of Patent: February 23, 2021Assignee: PFIZER INC.Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
-
Publication number: 20200102394Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.Type: ApplicationFiled: August 8, 2019Publication date: April 2, 2020Applicant: PFIZER INC.Inventors: Shu-Hui LIU, Flavia Mercer PERNASETTI, Wei-Hsien HO
-
Patent number: 10421815Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.Type: GrantFiled: October 22, 2018Date of Patent: September 24, 2019Assignee: Pfizer Inc.Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
-
Publication number: 20190092867Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.Type: ApplicationFiled: October 22, 2018Publication date: March 28, 2019Applicant: PFIZER INC.Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Weihsien Ho
-
Publication number: 20190002559Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: ApplicationFiled: September 7, 2018Publication date: January 3, 2019Applicant: RINAT NEUROSCIENCE CORP.Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
-
Patent number: 10144781Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.Type: GrantFiled: May 31, 2017Date of Patent: December 4, 2018Assignee: Pfizer Inc.Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
-
Patent number: 10100114Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: GrantFiled: May 20, 2016Date of Patent: October 16, 2018Assignee: RINAT NEUROSCIENCE CORP.Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
-
Publication number: 20180002428Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.Type: ApplicationFiled: May 31, 2017Publication date: January 4, 2018Applicant: PFIZER INC.Inventors: Shu-Hui LIU, Flavia Mercer PERNASETTI, Weihsien HO
-
Publication number: 20170313787Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.Type: ApplicationFiled: May 11, 2017Publication date: November 2, 2017Applicants: PFIZER INC., RINAT NEUROSCIENCE CORP.Inventors: Pavel STROP, Magdalena Grazyna DORYWALSKA, Arvind RAJPAL, David SHELTON, Shu-Hui LIU, Jaume PONS, Russell DUSHIN
-
Patent number: 9708405Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.Type: GrantFiled: August 1, 2014Date of Patent: July 18, 2017Assignee: PFIZER INC.Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho